Program

Asebio Investor Day 2022

Program

Asebio Investor Day 2022

27 April, 2022

Welcome Reception

AseBio Investor Day participants can join us for a cocktail style Welcome Reception. A fun way to start the event networking in a breathtaking historical venue in the heart of Madrid.

Date:

Wednesday, 27 April 2022

Time:

8.30pm – 10.00pm

Venue:

Palacio de la Bolsa de Madrid – Madrid Stock Exchange Palace Building
Plaza de la Lealtad, 1
Madrid

Welcome remarks:

Jesus González Nieto-Marquez, CEO, BME-Growth

Manuel García-Sañudo, CEO, Arquimea Group

Ion Arocena, CEO, AseBio

Dress:

Smart casual

About the venue

The Madrid Stock Exchange or Bolsa de Madrid is the oldest existing stock exchange in Spain and one of the oldest in the world. It was founded in 1831 by King Fernando VII and the first trading session took place in late October. The Madrid Stock Exchange Palace building, inaugurated in 1893 in presence of the Queen Regent María Cristina, turns 129 in 2022.

It is a building of outstanding architectural and symbolic value. Located in the heart of Madrid, in an area recently designated as World Heritage Site by UNESCO, the building was erected on land donated by the Crown and it is still today the financial centre and the main headquarter of BME and the Madrid Stock Exchange, Gold Sponsor of the AseBio Investor Day.

Year after year, it receives more than 65,000 visitors who attend numerous meetings with investors, IPOs, academic ceremonies, and other financial events.

AseBio Investor Day 2022 Program

8:30 - 9:00

Registration & badge pick-up

9:00 - 9:30

Welcome Remarks

  • Elisa Carbonell, General Director of Internationalization, ICEX – Spanish Foreign Trade Institute
  • Ana Polanco, President, AseBio – Spanish Bioindustry Association

9:30 - 10:00

Spain's 2021 biotechnology investment & deals review

The AseBio Investor Day program will start with a review of the latest statistics regarding private investment for the year 2021 in the biotech industry.

Spain’s biotech industry has been increasingly successful at attracting financing capital from private resources, with a constant growth since the year 2016.

Several VC deals, financing from capital markets and a increasing M&A activity positions Spain as one of the more dynamic countries in Europe. International investors are part of this trend too, co- investing with their Spanish counterparts in several deals.

Join us in this presentation to learn if this growth trend has also been consolidated during 2021 and what are the prospects for the short-midterm in Spain.

Speakers:

  • Ion Arocena, Managing Director, AseBio – Spanish Bioindustry Association
  • Alberto Sanz, Director of Financing & Investor Relations, ICEX-Invest in Spain

10:00 - 12:00

Pitch presentations

10:00 Ability Pharmaceuticals
10:06 Allinky Biopharma SL
10:12 AON Therapeutics – CRG
10:18 Biohope Scientific Solutions
10:24 MOA Foodtech
10:30 FIIS_FJD  / Project 1: Differential Biomarkers of Asthma
10:36 FIIS_FJD/  Project 2: Sensitive Drainage System
10:42 Gate2Brain
10:48 Immuno Coaching
10:54 Inhibitec Anticuerpos S.L.
11:00 Laminar Pharma
11:06 MiMARK
11:12 DISIT Biotech
11:18 Nanoligent S.L.
11:24 Neurofix S.A.
11:30 NUCAPS Nanotechnology – Microencapsulated probiotics
11:36 Oniria Therapeutics  S.L.
11:42 Palmeera
11:48 Vaxdyn

12:00 - 13:00

From academia to industry: lessons learned building a successful biotech company

The journey to create and grow from academia a successful biotech start-up is long and carries a high risk of failure. Many companies struggle to define the roadmap towards success and to bridge the gap from being a start-up towards reaching an IPO, sale the company or launch their product into the market.

Fortunately, during the last decade Spain has produced several successful companies that can serve not only as great examples to learn from their achievements, but also from their mistakes.

Topics such as the science behind the company, building the team, raising cash or the decision-making process will be discussed by the founders of some of the most successful biotech companies and venture capital firms in Spain.

Moderator:

  • Leticia Rodriguez Vadillo, Partner, Life Sciences-Pharma, PwC (Spain)

Speakers:

  • Carlos Buesa, CEO & Co-Founder, Oryzon Genomics
  • Clara Campás, CEO & Co-Founder, Asabys Partners
  • Joan Perelló, Founder & CEO, Sanifit
  • Joel Jean-Mairet, Managing Partner, Ysios Capital

13:00 - 14:00

Boosting tech transfer in Biotechnology – turning ideas into technological solutions for society.

In 2020, Spain became the 8th world power in the biotech sector and for the first time, the turnover of the sector accounted for 1% of the national GDP. In overall numbers, however, Spain keeps lagging in innovation ranking far behind from highly innovative countries despite holding a top 10 position in scientific production in biotechnology worldwide. Whereas biotech companies account for a large amount of the patent applications and patents granted, universities and public research centres also substantially contribute, and joint patenting accounts for the larger number in the biotech sector.

How can we boost the technology transfer from academia to society to harness inventions and biotechnologies that are conceived in research centers? The tech transfer field has rapidly evolved in the last decade with a more mature ecosystem that brings together private investors, academia and biotechnology and pharma companies to identify ideas that can create a positive impact in the progress and health of society. An increasingly demanding and competitive system requires that all actors of the ecosystem identify common ground to build and help grow disruptive technologies and successful companies.

The panel will discuss new ways to collaborate and join efforts to streamline and improve the process of technology transfer from different perspectives that will open new doors to a more efficient innovation in biotechnology.

Sponsored by:     

Moderator:

  • Carolina Pola, Innovation Strategist, Kaudal (Spain)

Speakers:

  • Clara Campás, CEO & Co-Founder, Asabys Partners
  • Esther Riambau, CEO Oniria Therapeutics
  • Juan Ignacio Imbaud, CEO, Protein Alternatives
  • Antonio Gómez, Associate Director Alliance Manager, Janssen Pharmaceutical, J&J (Spain)

14:00 - 15:30

Lunch Break

15:30 - 16:15

Alternative funding options for biotech companies

Raising money for a biotech startup can be challenging and sometimes venture capital is not the only option to fund a life sciences company.
Alternatives to venture capital are many options, from family offices to crowfunding platforms, although in this panel we will focus on non-dilutive financing in the form of grants and loans.
Non-dilutive funding can be very attractive and make the difference for a biotech company, because it retains value and it also helps the company advance to the point where an investor or a partner can be found.
Panellists from top Spanish & European institutions will share with the audience the different possibilities available in this field for the biotech companies.

Moderator:

  • Carmen Eibe, Director, Project Coordination, Pharmamar

Speakers

  • Jose Bayon, CEO, ENISA
  • Juan Luis Romera, Advisor/Manager in the Department of Institutional Promotion and Territorial Cooperation, CDTI

16:15 - 17:00

Pharma Presentations

Novartis

Johnson & Johnson Innovation

17:00 - 17:45

Early Stage Investments

Currently, Spain is ranked 8th in terms of biotech scientific production with leading institutions at the forefront of scientific research. However, this hasn’t always translated into the strong investment figures needed to develop the industry as it should be, so these new technologies and innovations can reach ultimately society in general.
However, Spain’s VC investment in biotechnology is currently growing at double-digit growth, with record investment figures, more players developing a strong local investment ecosystem and foreign VCs that see Spain as a country of untapped opportunities, many of them in early-stage companies.
In this session, we will discuss how the investment landscape in early stage is evolving in Spain and what can we expect in the short/mid-term.

Moderator:

  • Santiago Lozano, Associate, Tech Transfer Funds Director, Clave Capital

Speakers:

  • Laura Rodriguez, Principal, InVivo Capital
  • Andres Ubierna, Head of Capitalization of Technology Companies, CDTI
  • Edoardo Negroni, Co-Founder & Managing Partner, AurorA Science

17:45 - 18:30

1st AseBio - PwC Awards Ceremony

Categories:

- Startup of the year

- Biotech company of the year

- Most relevant investment deal

- Most relevant M&A

- Venture capital firm of the year

Closing remarks

Hosted by:

Sponsored by:

27 April

Welcome Reception

Venue to be announced soon

AseBio Investor Day 2022 Program

8:30 - 9:00

Registration & badge pick-up

9:00 - 9:30

Welcome Remarks

  • Elisa Carbonell, General Director of Internationalization, ICEX – Spanish Foreign Trade Institute
  • Ana Polanco, President, AseBio – Spanish Bioindustry Association

9:30 - 10:00

Spain's 2021 biotechnology investment & deals review

The AseBio Investor Day program will start with a review of the latest statistics regarding private investment for the year 2021 in the biotech industry.

Spain’s biotech industry has been increasingly successful at attracting financing capital from private resources, with a constant growth since the year 2016.

Several VC deals, financing from capital markets and a increasing M&A activity positions Spain as one of the more dynamic countries in Europe. International investors are part of this trend too, co- investing with their Spanish counterparts in several deals.

Join us in this presentation to learn if this growth trend has also been consolidated during 2021 and what are the prospects for the short-midterm in Spain.

Speakers:

  • Ion Arocena, Managing Director, AseBio – Spanish Bioindustry Association
  • Alberto Sanz, Director of Financing & Investor Relations, ICEX-Invest in Spain

10:00 - 12:00

Pitch presentations

10:00 Ability Pharmaceuticals
10:06 Allinky Biopharma SL
10:12 AON Therapeutics – CRG
10:18 Biohope Scientific Solutions
10:24 MOA Foodtech
10:30 FIIS_FJD  / Project 1: Differential Biomarkers of Asthma
10:36 FIIS_FJD/  Project 2: Sensitive Drainage System
10:42 Gate2Brain
10:48 Immuno Coaching
10:54 Inhibitec Anticuerpos S.L.
11:00 Laminar Pharma
11:06 MiMARK
11:12 DISIT Biotech
11:18 Nanoligent S.L.
11:24 Neurofix S.A.
11:30 NUCAPS Nanotechnology – Microencapsulated probiotics
11:36 Oniria Therapeutics  S.L.
11:42 Palmeera
11:48 Vaxdyn

12:00 - 13:00

From academia to industry: lessons learned building a successful biotech company

The journey to create and grow from academia a successful biotech start-up is long and carries a high risk of failure. Many companies struggle to define the roadmap towards success and to bridge the gap from being a start-up towards reaching an IPO, sale the company or launch their product into the market.

Fortunately, during the last decade Spain has produced several successful companies that can serve not only as great examples to learn from their achievements, but also from their mistakes.

Topics such as the science behind the company, building the team, raising cash or the decision-making process will be discussed by the founders of some of the most successful biotech companies and venture capital firms in Spain.

Moderator:

  • Leticia Rodriguez Vadillo, Partner, Life Sciences-Pharma, PwC (Spain)

Speakers:

  • Carlos Buesa, CEO & Co-Founder, Oryzon Genomics
  • Clara Campás, CEO & Co-Founder, Asabys Partners
  • Joan Perelló, Founder & CEO, Sanifit
  • Joel Jean-Mairet, Managing Partner, Ysios Capital

13:00 - 14:00

Boosting tech transfer in Biotechnology – turning ideas into technological solutions for society.

In 2020, Spain became the 8th world power in the biotech sector and for the first time, the turnover of the sector accounted for 1% of the national GDP. In overall numbers, however, Spain keeps lagging in innovation ranking far behind from highly innovative countries despite holding a top 10 position in scientific production in biotechnology worldwide. Whereas biotech companies account for a large amount of the patent applications and patents granted, universities and public research centres also substantially contribute, and joint patenting accounts for the larger number in the biotech sector.

How can we boost the technology transfer from academia to society to harness inventions and biotechnologies that are conceived in research centers? The tech transfer field has rapidly evolved in the last decade with a more mature ecosystem that brings together private investors, academia and biotechnology and pharma companies to identify ideas that can create a positive impact in the progress and health of society. An increasingly demanding and competitive system requires that all actors of the ecosystem identify common ground to build and help grow disruptive technologies and successful companies.

The panel will discuss new ways to collaborate and join efforts to streamline and improve the process of technology transfer from different perspectives that will open new doors to a more efficient innovation in biotechnology.

Sponsored by:     

Moderator:

  • Carolina Pola, Innovation Strategist, Kaudal (Spain)

Speakers:

  • Clara Campás, CEO & Co-Founder, Asabys Partners
  • Esther Riambau, CEO Oniria Therapeutics
  • Juan Ignacio Imbaud, CEO, Protein Alternatives
  • Antonio Gómez, Associate Director Alliance Manager, Janssen Pharmaceutical, J&J (Spain)

14:00 - 15:30

Lunch Break

15:30 - 16:15

Alternative funding options for biotech companies

Raising money for a biotech startup can be challenging and sometimes venture capital is not the only option to fund a life sciences company.
Alternatives to venture capital are many options, from family offices to crowfunding platforms, although in this panel we will focus on non-dilutive financing in the form of grants and loans.
Non-dilutive funding can be very attractive and make the difference for a biotech company, because it retains value and it also helps the company advance to the point where an investor or a partner can be found.
Panellists from top Spanish & European institutions will share with the audience the different possibilities available in this field for the biotech companies.

Moderator:

  • Carmen Eibe, Director, Project Coordination, Pharmamar

Speakers

  • Jose Bayon, CEO, ENISA
  • Juan Luis Romera, Advisor/Manager in the Department of Institutional Promotion and Territorial Cooperation, CDTI

16:15 - 17:00

Pharma Presentations

Novartis

Johnson & Johnson Innovation

17:00 - 17:45

Early Stage Investments

Currently, Spain is ranked 8th in terms of biotech scientific production with leading institutions at the forefront of scientific research. However, this hasn’t always translated into the strong investment figures needed to develop the industry as it should be, so these new technologies and innovations can reach ultimately society in general.
However, Spain’s VC investment in biotechnology is currently growing at double-digit growth, with record investment figures, more players developing a strong local investment ecosystem and foreign VCs that see Spain as a country of untapped opportunities, many of them in early-stage companies.
In this session, we will discuss how the investment landscape in early stage is evolving in Spain and what can we expect in the short/mid-term.

Moderator:

  • Santiago Lozano, Associate, Tech Transfer Funds Director, Clave Capital

Speakers:

  • Laura Rodriguez, Principal, InVivo Capital
  • Andres Ubierna, Head of Capitalization of Technology Companies, CDTI
  • Edoardo Negroni, Co-Founder & Managing Partner, AurorA Science

17:45 - 18:30

1st AseBio - PwC Awards Ceremony

Categories:

- Startup of the year

- Biotech company of the year

- Most relevant investment deal

- Most relevant M&A

- Venture capital firm of the year

Closing remarks

Hosted by:

Sponsored by: